|
Osteoporosis, Postmenopausal
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Introduction</b>: Bazedoxifene (BZD) is a third-generation selective estrogen receptor modulator approved for the treatment of postmenopausal osteoporosis with additional favorable effects in lipids, uterine and breast tissue.
|
31091133 |
2019 |
|
Osteoporosis, Postmenopausal
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Altogether, LMV in early PMO suppresses its progression, which is associated with osteogenic differentiation of rBMSCs via up-regulation of ERα and activation of the canonical Wnt pathway.
|
31406012 |
2019 |
|
Osteoporosis, Postmenopausal
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, DHTKD1 and RBBP4 may be involved in PMOP by regulating mitochondrial dysfunction and interacting with ESR1, respectively.
|
30569177 |
2019 |
|
Osteoporosis, Postmenopausal
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
ERα G2014A was significantly associated with a decreased risk of PMOP in Caucasian populations.
|
29458346 |
2018 |
|
Osteoporosis, Postmenopausal
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The experimental studies indicated their potential use as treatment for postmenopausal osteoporosis and investigated the underlying mechanisms including osteoprotegerin/receptor activator of nuclear factor κB ligand (OPG/RANKL), extracellular-signal-regulated kinase/c-Jun N terminal kinase/mitogen-activated protein kinase (ERK/JNK/MAPK), estrogen receptor (ER), bone morphogenetic protein (BMP), transforming growth factor (TGF)-β, Wnt/β-catenin, and Notch signaling pathways.
|
29151553 |
2017 |
|
Osteoporosis, Postmenopausal
|
0.100 |
Biomarker
|
disease |
BEFREE |
A series of interactions, such as CSTA/TYROBP, CCNE1/REL and TUBA1B/ESR1 might play pivotal roles in the occurrence and development of PMO.
|
26676054 |
2016 |
|
Osteoporosis, Postmenopausal
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Therefore, ESR1 polymorphisms at rs2234693 and rs9340799 may be associated with OP, and could be used as markers to screen those with high risks to postmenopausal OP in Chinese women.
|
27323138 |
2016 |
|
Osteoporosis, Postmenopausal
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
several studies have investigated the relationship between the estrogen receptor (ER) gene polymorphisms and the efficacy of estrogen replacement therapy in postmenopausal osteoporosis.
|
26001094 |
2015 |
|
Osteoporosis, Postmenopausal
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aims of the study were as follows: (1) To identify the differences in spinal body mass density (BMD) in relation to polymorphism in vitamin D receptor (VDR) and estrogen receptor-alpha (ERalpha) genes in untreated women with postmenopausal osteoporosis.
|
19903038 |
2009 |
|
Osteoporosis, Postmenopausal
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our results highlight the significance of B cells in the etiology of osteoporosis and suggest a novel mechanism for postmenopausal osteoporosis (i.e., that downregulation of ESR1 and MAPK3 in B cells regulates secretion of factors, leading to increased osteoclastogenesis or decreased osteoblastogenesis).
|
18433299 |
2008 |
|
Osteoporosis, Postmenopausal
|
0.100 |
Biomarker
|
disease |
BEFREE |
By contrast, multilocus analysis predicted epistatic interactions between ESR1, ESR2 and NRIP1 loci and its involvement in postmenopausal osteoporosis (P=0.003).
|
16530497 |
2006 |
|
Osteoporosis, Postmenopausal
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We have recently identified a synonymous single nucleotide polymorphism (SNP) in exon 8 of estrogen receptor-alpha (ERalpha) gene in the vicinity of the stop codon (G2014A) that is associated with an increased risk of postmenopausal osteoporosis.
|
15647972 |
2005 |
|
Osteoporosis, Postmenopausal
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Association of oestrogen receptor alpha gene polymorphisms with postmenopausal bone loss, bone mass, and quantitative ultrasound properties of bone.
|
15744038 |
2005 |
|
Osteoporosis, Postmenopausal
|
0.100 |
Biomarker
|
disease |
BEFREE |
Carriage of SNPs predisposing to early postmenopausal bone loss and osteoporosis (ER-alpha and VDR) were found in 26.7% of women.
|
15237001 |
2004 |
|
Osteoporosis, Postmenopausal
|
0.100 |
GeneticVariation
|
disease |
LHGDN |
The ER alpha genotype associations were statistically significant in explaining the rate of perimenopausal bone loss and its turnover; however, BMI or becoming postmenopausal contributed more to the magnitude of the difference in bone change.
|
14764789 |
2004 |
|
Osteoporosis, Postmenopausal
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Association of a G2014A transition in exon 8 of the estrogen receptor-alpha gene with postmenopausal osteoporosis.
|
11846326 |
2001 |
|
Osteoporosis, Postmenopausal
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Early postmenopausal bone loss is associated with PvuII estrogen receptor gene polymorphism in Finnish women: effect of hormone replacement therapy.
|
10703934 |
2000 |
|
Osteoporosis, Postmenopausal
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We suggest that some variation of the ER gene linked to these RFLPs is associated with low BMD and that this at least partly explains the cause of postmenopausal osteoporosis in Japanese women.
|
8852941 |
1996 |